EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
Dowell
Jonathan E
JE
University of Texas Southwestern Medical Center, Dallas, TX 75390-8593, USA.
Minna
John D
JD
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D018628:Gene Dosage; D018773:Genes, erbB-1; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000077156:Gefitinib